Sinopharm Vaccine - Product Scorecard

Company: Sinopharm

Type: Covid-19 Vaccine
Product (brand name): BBIBP-CorV (Covilo)
0%
compliance
with criteria
Share this score on social:

Other company scores

Bharat Biotech Vaccine
0%
Brii BioSciences Therapeutic
0%
CanSino Vaccine
0%
Celltrion Therapeutic
0%
CIGB Vaccine
0%
Texas Children’s Hospital Vaccine
0%
Finlay Vaccine
0%
Gamaleya Vaccine
0%
Gilead Therapeutic
0%
Johnson & Johnson Vaccine
0%
Moderna Vaccine
0%
Vaxine Vaccine
0%
Vektor Vaccine
0%
Zydus Vaccine
0%
AstraZeneca Antibody
0%
AstraZeneca Vaccine
0%
Eli Lilly Therapeutic 3
0%
Eli Lilly Therapeutic 2
0%
Eli Lilly Therapeutic 1
0%
MSD Therapeutic
0%
Novavax Vaccine
0%
Pfizer Therapeutic
0%
Pfizer Vaccine
0%
Regeneron Therapeutic
0%
Roche Therapeutic
0%
Sanofi Vaccine
0%
Sinopharm Vaccine
0%
Sinovac Vaccine
0%
GSK Therapeutic
0%
Explore the results of PAF’s research into the behaviour of Sinopharm. Each section is given an overall score; individual criteria are also scored (see icon following the criteria heading).

Click on ‘Explanation about the score’ sign next to each entry to expand and learn more.

Category A: Commitments and Accountability

The company should publicly commit to human rights in relation to product development and marketing, by adopting an official human rights policy statement recognising the right to the highest attainable standard of health. The company should endeavour to integrate human rights into its strategies, policies, programmes, projects, and activities.

The company should also have a publicly available global access plan for their Covid-19 product, based on human rights standards, with measurable targets and lines of accountability.

A1: Does Sinopharm publish a global access plan for its product?

At the Sustainable Development Forum 2021, Liu Jingzhen, Chairman of China National Pharmaceutical Group Co., Ltd stated that Sinopharm plans to rapidly expand production capacity; participate in global distribution mechanisms (donate doses to COVAX); and enhance local production and supply capacity through cooperation agreements.

See more company scores
Zydus Vaccine
ZFSW Vaccine
Vektor Vaccine
Vaxine Vaccine
Texas Children’s Hospital Vaccine
Sinovac Vaccine
Sanofi Vaccine
Roche Therapeutic
Regeneron Therapeutic
Pfizer Vaccine
Pfizer Therapeutic
Novavax Vaccine
MSD Therapeutic
Moderna Vaccine
Johnson & Johnson Vaccine
GSK Therapeutic
Gilead Therapeutic
Gamaleya Vaccine
Finlay Vaccine
Eli Lilly Therapeutic 3
Eli Lilly Therapeutic 2
Eli Lilly Therapeutic 1
CIGB Vaccine
Celltrion Therapeutic
CanSino Vaccine
Brii BioSciences Therapeutic
Bharat Biotech Vaccine
AstraZeneca Vaccine
AstraZeneca Antibody
A2: Does Sinopharm commit to comply with human rights standards in relation to product development and marketing?

Sinopharm mentions ‘social responsibility’ on its website, but does not mention human rights explicitly.

See more company scores
Zydus Vaccine
ZFSW Vaccine
Vektor Vaccine
Vaxine Vaccine
Texas Children’s Hospital Vaccine
Sinovac Vaccine
Sanofi Vaccine
Roche Therapeutic
Regeneron Therapeutic
Pfizer Vaccine
Pfizer Therapeutic
Novavax Vaccine
MSD Therapeutic
Moderna Vaccine
Johnson & Johnson Vaccine
GSK Therapeutic
Gilead Therapeutic
Gamaleya Vaccine
Finlay Vaccine
Eli Lilly Therapeutic 3
Eli Lilly Therapeutic 2
Eli Lilly Therapeutic 1
CIGB Vaccine
Celltrion Therapeutic
CanSino Vaccine
Brii BioSciences Therapeutic
Bharat Biotech Vaccine
AstraZeneca Vaccine
AstraZeneca Antibody

Category C: International cooperation

The company should constructively engage with international initiatives for the equitable distribution of vaccines and therapeutics, such as the Covid-19 Technology Access Pool (C-TAP) or the Medicines Patent Pool (MPP), and the ACT Accelerator (COVAX). The company should also publicly commit to not enforcing the exclusive rights of Covid-19 related patents, and enter into non-exclusive, transparent licensing agreements for its Covid-19 products with other companies.

C1: Does Sinopharm commit to C-TAP or MPP?

Sinopharm does not commit to C-TAP or the MPP.

See more company scores
Zydus Vaccine
ZFSW Vaccine
Vektor Vaccine
Vaxine Vaccine
Texas Children’s Hospital Vaccine
Sinovac Vaccine
Sanofi Vaccine
Roche Therapeutic
Regeneron Therapeutic
Pfizer Vaccine
Pfizer Therapeutic
Novavax Vaccine
MSD Therapeutic
Moderna Vaccine
Johnson & Johnson Vaccine
GSK Therapeutic
Gilead Therapeutic
Gamaleya Vaccine
Finlay Vaccine
Eli Lilly Therapeutic 3
Eli Lilly Therapeutic 2
Eli Lilly Therapeutic 1
CIGB Vaccine
Celltrion Therapeutic
CanSino Vaccine
Brii BioSciences Therapeutic
Bharat Biotech Vaccine
AstraZeneca Vaccine
AstraZeneca Antibody
C2: Does Sinopharm commit to not enforcing the exclusive rights of Covid-19 related patents?

China is supportive of vaccine diplomacy and the patent waiver, and Sinopharm is a state-backed enterprise. However, Sinopharm has not made an explicit commitment to enforce patents.

See more company scores
Zydus Vaccine
ZFSW Vaccine
Vektor Vaccine
Vaxine Vaccine
Texas Children’s Hospital Vaccine
Sinovac Vaccine
Sanofi Vaccine
Roche Therapeutic
Regeneron Therapeutic
Pfizer Vaccine
Pfizer Therapeutic
Novavax Vaccine
MSD Therapeutic
Moderna Vaccine
Johnson & Johnson Vaccine
GSK Therapeutic
Gilead Therapeutic
Gamaleya Vaccine
Finlay Vaccine
Eli Lilly Therapeutic 3
Eli Lilly Therapeutic 2
Eli Lilly Therapeutic 1
CIGB Vaccine
Celltrion Therapeutic
CanSino Vaccine
Brii BioSciences Therapeutic
Bharat Biotech Vaccine
AstraZeneca Vaccine
AstraZeneca Antibody
C3: Does Sinopharm supply to, or signs agreements with, the vaccines or therapeutics pillar of the ACT Accelerator?

Sinopharm has donated 170 million doses to COVAX.

See more company scores
Zydus Vaccine
ZFSW Vaccine
Vektor Vaccine
Vaxine Vaccine
Texas Children’s Hospital Vaccine
Sinovac Vaccine
Sanofi Vaccine
Roche Therapeutic
Regeneron Therapeutic
Pfizer Vaccine
Pfizer Therapeutic
Novavax Vaccine
MSD Therapeutic
Moderna Vaccine
Johnson & Johnson Vaccine
GSK Therapeutic
Gilead Therapeutic
Gamaleya Vaccine
Finlay Vaccine
Eli Lilly Therapeutic 3
Eli Lilly Therapeutic 2
Eli Lilly Therapeutic 1
CIGB Vaccine
Celltrion Therapeutic
CanSino Vaccine
Brii BioSciences Therapeutic
Bharat Biotech Vaccine
AstraZeneca Vaccine
AstraZeneca Antibody
C4: Does Sinopharm agree to license its Covid-19 medical products to other companies?

Sinopharm has made deals with G42  in the UAE to produce the vaccine under the name Hayat-vax. This seems to be a fill and finish agreement. Sinopharm has another fill-and-finish site at Duopharma Biotech in Malaysia.

 

See more company scores
Zydus Vaccine
ZFSW Vaccine
Vektor Vaccine
Vaxine Vaccine
Texas Children’s Hospital Vaccine
Sinovac Vaccine
Sanofi Vaccine
Roche Therapeutic
Regeneron Therapeutic
Pfizer Vaccine
Pfizer Therapeutic
Novavax Vaccine
MSD Therapeutic
Moderna Vaccine
Johnson & Johnson Vaccine
GSK Therapeutic
Gilead Therapeutic
Gamaleya Vaccine
Finlay Vaccine
Eli Lilly Therapeutic 3
Eli Lilly Therapeutic 2
Eli Lilly Therapeutic 1
CIGB Vaccine
Celltrion Therapeutic
CanSino Vaccine
Brii BioSciences Therapeutic
Bharat Biotech Vaccine
AstraZeneca Vaccine
AstraZeneca Antibody

Category E: Equality, non-discrimination & equity

The company should engage in efforts to further equitable distribution of Covid-19 vaccines/therapeutics, by equitably distributing its supplies globally, devising fair pricing strategies, and making the active ingredient for its product available to other manufacturers. The company should also engage in full technology transfer to other manufacturers, including the necessary transfer of skills, legal components, knowledge and intellectual property. Where applicable, the company should agree to waive rights in regulatory test data, and refrain from enforcing TRIPS+ measures.

E1: Does Sinopharm make the active ingredient available on reasonable grounds? [Only for therapeutics]

[Only applies to therapeutics]

See more company scores
Zydus Vaccine
ZFSW Vaccine
Vektor Vaccine
Vaxine Vaccine
Texas Children’s Hospital Vaccine
Sinovac Vaccine
Sanofi Vaccine
Roche Therapeutic
Regeneron Therapeutic
Pfizer Vaccine
Pfizer Therapeutic
Novavax Vaccine
MSD Therapeutic
Moderna Vaccine
Johnson & Johnson Vaccine
GSK Therapeutic
Gilead Therapeutic
Gamaleya Vaccine
Finlay Vaccine
Eli Lilly Therapeutic 3
Eli Lilly Therapeutic 2
Eli Lilly Therapeutic 1
CIGB Vaccine
Celltrion Therapeutic
CanSino Vaccine
Brii BioSciences Therapeutic
Bharat Biotech Vaccine
AstraZeneca Vaccine
AstraZeneca Antibody
E2: Does Sinopharm commit to full technology transfer to other manufacturers?

Sinopharm has entered into limited technology transfers to other manufacturers in the form of fill-and-finish sites (see C4).

See more company scores
Zydus Vaccine
ZFSW Vaccine
Vektor Vaccine
Vaxine Vaccine
Texas Children’s Hospital Vaccine
Sinovac Vaccine
Sanofi Vaccine
Roche Therapeutic
Regeneron Therapeutic
Pfizer Vaccine
Pfizer Therapeutic
Novavax Vaccine
MSD Therapeutic
Moderna Vaccine
Johnson & Johnson Vaccine
GSK Therapeutic
Gilead Therapeutic
Gamaleya Vaccine
Finlay Vaccine
Eli Lilly Therapeutic 3
Eli Lilly Therapeutic 2
Eli Lilly Therapeutic 1
CIGB Vaccine
Celltrion Therapeutic
CanSino Vaccine
Brii BioSciences Therapeutic
Bharat Biotech Vaccine
AstraZeneca Vaccine
AstraZeneca Antibody
E3: Does Sinopharm commit to non-profit, ‘fair’, or differential pricing?

Sinopharm’s prices for its vaccine range from 9 US dollars/dose (Argentina), to 36 US dollars/dose (Hungary). There is therefore some differential pricing, but the price paid by Argentina (a middle-income country) is only 1 quarter of what Hungary (a high-income country) paid. To be considered ‘fair’, the difference should be around 1 tenth (AstraZeneca’s non-profit price to Argentina, for example, was 4 US dollars/dose).

See more company scores
Zydus Vaccine
ZFSW Vaccine
Vektor Vaccine
Vaxine Vaccine
Texas Children’s Hospital Vaccine
Sinovac Vaccine
Sanofi Vaccine
Roche Therapeutic